{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:12:00Z","timestamp":1793945520902,"version":"4.8.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A significant proportion of patients with Crohn's disease (CD) require dose escalation or fail adalimumab (ADL) therapy over time. ADL, a monoclonal antibody directed against tumor necrosis factor, is approved for treatment of CD. Understanding pharmacokinetics (PK) of ADL is essential to optimize individual dosing in daily practice. The aim of this study was to evaluate PK of ADL in patients with CD and to identify factors that influence PK of ADL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In a retrospective cohort study, the authors reviewed the charts of 96 patients with CD receiving ADL induction and maintenance treatment. This patient cohort was used for external validation of population pharmacokinetic models of ADL available from literature. In addition, a novel population PK model was developed using nonlinear mixed-effects modeling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>None of the literature models properly described the PK of ADL in our cohort. Therefore, a novel population pharmacokinetic model was developed. Clearance of ADL increased 4-fold in the presence of anti-ADL antibodies. Patients who received ADL every week had a 40% higher clearance compared with patients receiving ADL every other week.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Clearance of ADL increased in the presence of anti-ADL antibodies and was associated with weekly ADL administrations. In clinical practice, the decision to intensify ADL treatment to weekly administrations is primarily based on disease activity. Increased disease activity may be the result of lower drug concentrations due to higher clearance. However, increased disease activity may also increase clearance due to increased target engagement. The causal relationship between these factors remains to be elucidated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000494","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T23:27:19Z","timestamp":1520810839000},"page":"202-211","source":"Crossref","is-referenced-by-count":40,"title":["Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease"],"prefix":"10.1097","volume":"40","author":[{"given":"Sophie E.","family":"Berends","sequence":"first","affiliation":[{"name":"Hospital Pharmacy and"},{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Strik","sequence":"additional","affiliation":[{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet C.","family":"Van Selm","sequence":"additional","affiliation":[{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y.","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Gastroenterology, Academic Medical Center Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohn's Colitis."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet."},{"key":"R4-20230928","article-title":"Adalimumab product approval information [Internet]","year":"2016","journal-title":"Cent Drug Eval Res."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000347190","article-title":"Top-down or step-up treatment in Crohn's disease?","volume":"31","author":"Rogler","year":"2013","journal-title":"Dig Dis."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00228-015-1892-1","article-title":"Pharmacokinetics of adalimumab in Crohn's disease","volume":"71","author":"Ternant","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","article-title":"Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2013-204185","article-title":"Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2010.09.005","article-title":"A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients","volume":"362","author":"Van Schouwenburg","year":"2010","journal-title":"J Immunol Methods."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2016.1216741","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"MAbs."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"General model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3147","article-title":"The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review","volume":"12","author":"Krieckaert","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/psp4.41","article-title":"A tutorial on target-mediated drug disposition (TMDD) models","volume":"4","author":"Dua","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","article-title":"Approximations of the target-mediated drug disposition model and identifiability of model parameters","volume":"35","author":"Gibiansky","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-7843.2005.pto960307.x","article-title":"On the prediction of the human response: a recycled mechanistic pharmacokinetic\/pharmacodynamic approach","volume":"96","author":"Meno-Tetang","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:06:57Z","timestamp":1695863217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000494","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}